Jean-Luc Fraikin's Biography

Jean-Luc Fraikin, CEO, Spectradyne

Dr Fraikin developed Spectradyne’s initial Microfluidic Resistive Pulse Sensing technology as part of his PhD thesis work at UC Santa Barbara in the research group of Dr. Andrew Cleland. After graduating he received postdoctoral training in cancer cell biology and biochemistry and worked in industry developing microfluidics-based molecular diagnostics. Dr. Fraikin is a co-founder of Spectradyne and now serves as the company’s CEO.

EV Quantification and Cargo Analysis with Spectradyne’s ARC™ Particle Analyzer

Wednesday, 26 July 2023 at 14:30

Add to Calendar ▼2023-07-26 14:30:002023-07-26 15:30:00Europe/LondonEV Quantification and Cargo Analysis with Spectradyne’s ARC™ Particle AnalyzerExtracellular Vesicles 2023: Technologies, Biomarker Cargo and Diagnostics in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com

Spectradyne’s ARC particle analyzer uses a unique combination of electrical and optical measurement techniques to accurately measure the size, concentration, and cargo of EVs as small as 50 nm in diameter. Examples of EV subpopulation analysis and cargo quantification will be presented, including measurements of a new standard material expressing both endogenous GFP and tetraspanin surface markers.

Add to Calendar ▼2023-07-26 00:00:002023-07-27 00:00:00Europe/LondonExtracellular Vesicles 2023: Technologies, Biomarker Cargo and DiagnosticsExtracellular Vesicles 2023: Technologies, Biomarker Cargo and Diagnostics in Orlando, FloridaOrlando, FloridaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors